Weiss Ratings Reiterates “Sell (E+)” Rating for SeaStar Medical (NASDAQ:ICU)

SeaStar Medical (NASDAQ:ICU)‘s stock had its “sell (e+)” rating restated by investment analysts at Weiss Ratings in a research report issued on Saturday,Weiss Ratings reports.

SeaStar Medical Price Performance

Shares of NASDAQ:ICU opened at $0.61 on Friday. The company’s 50 day simple moving average is $0.77 and its 200 day simple moving average is $0.90. The stock has a market capitalization of $20.93 million, a price-to-earnings ratio of -0.23 and a beta of -1.07. SeaStar Medical has a 1 year low of $0.31 and a 1 year high of $3.79.

SeaStar Medical (NASDAQ:ICU) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.25. The firm had revenue of $0.34 million during the quarter, compared to the consensus estimate of $0.25 million.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Trinity Financial Advisors LLC increased its stake in SeaStar Medical by 233.3% in the third quarter. Trinity Financial Advisors LLC now owns 50,000 shares of the company’s stock valued at $28,000 after acquiring an additional 35,000 shares during the last quarter. XTX Topco Ltd boosted its position in SeaStar Medical by 395.4% in the second quarter. XTX Topco Ltd now owns 60,983 shares of the company’s stock valued at $26,000 after buying an additional 48,674 shares in the last quarter. Finally, Armistice Capital LLC acquired a new stake in SeaStar Medical in the first quarter valued at approximately $1,018,000. 1.69% of the stock is owned by institutional investors.

About SeaStar Medical

SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome.